Aurobindo Pharma Ltd 2018 AR2
The report highlights Aurobindo Pharma Limited's financial and operational performance for the fiscal year 2017-18. The company achieved a consolidated revenue growth of 9.3% to reach INR 164,998 million, driven by strong performance in the US and European formulation markets. Key operational milestones included the commissioning of the Unit XVI Betalactum injectable facility in Jadcherla and the acquisition of Generis Farmaceutica S.A. in Portugal. On the sustainability front, the company established a 30 MW captive solar power plant in Andhra Pradesh to reduce its carbon footprint and actively engaged in community development programs focusing on education, healthcare, and safe drinking water.
Company: Aurobindo Pharma Ltd
Sector: Manufacturing
Country: India
Year: 2018
Type: AR2
Pages: 280
Back to company
Aurobindo Pharma Ltd
Annual Report
The report highlights Aurobindo Pharma Limited's financial and operational performance for the fiscal year 2017-18. The company achieved a consolidated revenue growth of 9.3% to reach INR 164,998 million, driven by strong performance in the US and European formulation markets. Key operational milestones included the commissioning of the Unit XVI Betalactum injectable facility in Jadcherla and the acquisition of Generis Farmaceutica S.A. in Portugal. On the sustainability front, the company established a 30 MW captive solar power plant in Andhra Pradesh to reduce its carbon footprint and actively engaged in community development programs focusing on education, healthcare, and safe drinking water.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Apr 1, 2017 - Mar 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees